Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non–Small Cell Lung Cancer
A longer treatment duration before discontinuation, a best objective response of CR/PR, PD-L1 ≥50%, and nonsquamous histology may help clinicians identify patients who may experience long-term disease control after discontinuation of ICI for irAE.
Authors
- Hira Rizvi (ORCID: https://orcid.org/0000-0002-8007-096X)
- Xinan Wang (ORCID: https://orcid.org/0000-0001-5236-1105)
- Adriana Barrichello (ORCID: https://orcid.org/0000-0003-1633-8236)
- Federica Pecci (ORCID: https://orcid.org/0009-0000-9289-2007)
- Adam J. Schoenfeld (ORCID: https://orcid.org/0000-0002-2644-1416)
- Rohit Thummalapalli (ORCID: https://orcid.org/0000-0002-8865-0299)
- Jacklynn V. Egger (ORCID: https://orcid.org/0000-0002-2180-4169)
- Mark Jeng (ORCID: https://orcid.org/0000-0003-0854-761X)
- Matthew D. Hellmann (ORCID: https://orcid.org/0000-0002-2670-9777)
- Biagio Ricciuti (ORCID: https://orcid.org/0000-0002-0651-2678)
- Victor R. Vaz (ORCID: https://orcid.org/0000-0003-3714-2814)
- Stephanie Alden (ORCID: https://orcid.org/0000-0003-0500-8696)
- Valentina Santo (ORCID: https://orcid.org/0009-0006-7587-9445)
- Arielle Elkrief (ORCID: https://orcid.org/0000-0003-1981-1535)
- Bruce E. Johnson (ORCID: https://orcid.org/0000-0002-5252-3677)
- Mizuki Nishino (ORCID: https://orcid.org/0000-0003-0275-0502)
- Alessandro Di Federico (ORCID: https://orcid.org/0000-0001-8877-4315)
- Malini Gandhi (ORCID: https://orcid.org/0000-0002-8006-4148)
- Giuseppe Lamberti (ORCID: https://orcid.org/0000-0003-3069-7630)
- Joao V. Alessi (ORCID: https://orcid.org/0000-0002-8072-5946)
- Mark M. Awad (ORCID: https://orcid.org/0000-0003-0928-5244)
- Guilherme Rossato de Almeida (ORCID: https://orcid.org/0009-0000-6073-6130)
- Peter Clark
Institutions
- Memorial Sloan Kettering Cancer Center (US)
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Dana-Farber Brigham Cancer Center (US)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2025-04-18
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-2990
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Institutes of Health